Literature DB >> 8567883

Comparative study of five methods for intratypic differentiation of polioviruses.

H G van der Avoort1, B P Hull, T Hovi, M A Pallansch, O M Kew, R Crainic, D J Wood, M N Mulders, A M van Loon.   

Abstract

A coded panel of 90 poliovirus isolates, 30 of each of the three known serotypes, was used to evaluate five methods for the intratypic differentiation of polioviruses: (i) an enzyme-linked immunosorbent assay with polyclonal cross-absorbed antisera (PAb-E), (ii) a neutralization assay with type-specific monoclonal antibodies (MAb-N), (iii) a restriction fragment length polymorphism (RFLP) assay, (iv) a Sabin vaccine strain-specific PCR assay, and (v) a Sabin vaccine strain-specific cRNA probe hybridization (ProHyb) assay. Sequence analysis was used for the definitive characterization of the strains. The panel was distributed to five laboratories; each laboratory analyzed the strains by at least two methods. Each method was used by three or four laboratories. The total performance scores (percentage correct results per number of tests) of the five methods were 96.7% for PAb-E, 93.9% for MAb-N, 91.9% for RFLP assay, 93.3% for Sabin vaccine strain-specific PCR, and 97.4% for Sabin vaccine strain-specific ProHyb. Consistent results were obtained by each laboratory for 88 of 90 isolates (97.8%) examined by PAb-E, 81 of 90 isolates (90.0%) examined by MAb-N, 78 of 90 isolates (86.7%) examined by RFLP assay, 81 of 90 isolates (90.0%) examined by PCR, and 89 of 90 isolates (98.9%) examined by ProHyb assay. Six strains were classified differently by different methods. It is recommended that at least two methods be used for the intratypic differentiation of poliovirus isolates, and each method should be based on a different principle (i.e., antigenic properties and nucleotide sequence composition). If two assays yield discrepant results, further characterization, preferably by partial sequence determination, will be required for correct identification.

Entities:  

Mesh:

Year:  1995        PMID: 8567883      PMCID: PMC228529          DOI: 10.1128/jcm.33.10.2562-2566.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Genotype-specific in vitro amplification of sequences of the wild type 3 polioviruses from Mexico and Guatemala.

Authors:  C F Yang; L De; S J Yang; J Ruiz Gómez; J R Cruz; B P Holloway; M A Pallansch; O M Kew
Journal:  Virus Res       Date:  1992-08       Impact factor: 3.303

2.  Intratypic serodifferentiation of poliomyelitis virus strains by strain-specific antisera.

Authors:  A L van Wezel; A G Hazendonk
Journal:  Intervirology       Date:  1979       Impact factor: 1.763

3.  Molecular epidemiology of wild poliovirus type 1 in Europe, the Middle East, and the Indian subcontinent.

Authors:  M N Mulders; G Y Lipskaya; H G van der Avoort; M P Koopmans; O M Kew; A M van Loon
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

4.  Direct detection of wild poliovirus circulation by stool surveys of healthy children and analysis of community wastewater.

Authors:  G Tambini; J K Andrus; E Marques; J Boshell; M Pallansch; C A de Quadros; O Kew
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

5.  Differentiation of vaccine and wild-type polioviruses using polymerase chain reaction and restriction enzyme analysis.

Authors:  B Schweiger; E Schreier; B Böthig; J M López-Pila
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

6.  Differentiation between wild and vaccine-derived strains of poliovirus by stringent microplate hybridization of PCR products.

Authors:  N Takeda; K Sakae; M Agboatwalla; S Isomura; R Hondo; S Inouye
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

7.  The WHO-EPI initiative for the global eradication of poliomyelitis.

Authors:  N A Ward; J B Milstien; H F Hull; B P Hull; R J Kim-Farley
Journal:  Biologicals       Date:  1993-12       Impact factor: 1.856

8.  Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera.

Authors:  A D Osterhaus; A L van Wezel; T G Hazendonk; F G UytdeHaag; J A van Asten; B van Steenis
Journal:  Intervirology       Date:  1983       Impact factor: 1.763

9.  Identification of vaccine-related polioviruses by hybridization with specific RNA probes.

Authors:  L De; B Nottay; C F Yang; B P Holloway; M Pallansch; O Kew
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

10.  Isolation of epidemic poliovirus from sewage during the 1992-3 type 3 outbreak in The Netherlands.

Authors:  H G van der Avoort; J H Reimerink; A Ras; M N Mulders; A M van Loon
Journal:  Epidemiol Infect       Date:  1995-06       Impact factor: 2.451

View more
  48 in total

1.  Enterovirus surveillance of Italian healthy children.

Authors:  A M Patti; A L Santi; L Fiore; L Vellucci; D De Stefano; E Bellelli; S Barbuti; G M Fara
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  A double-selective tissue culture system for isolation of wild-type poliovirus from sewage applied in a long-term environmental surveillance.

Authors:  Y Manor; R Handsher; T Halmut; M Neuman; B Abramovitz; A Mates; E Mendelson
Journal:  Appl Environ Microbiol       Date:  1999-04       Impact factor: 4.792

3.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.

Authors:  Javier Martín; Elena Samoilovich; Glynis Dunn; Angie Lackenby; Esphir Feldman; Alan Heath; Ekaterina Svirchevskaya; Gill Cooper; Marina Yermalovich; Philip D Minor
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Multiplex PCR method for identifying recombinant vaccine-related polioviruses.

Authors:  David R Kilpatrick; Karen Ching; Jane Iber; Ray Campagnoli; Christopher J Freeman; Nada Mishrik; Hong-Mei Liu; Mark A Pallansch; Olen M Kew
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

6.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  Use of a multiple restriction fragment length polymorphism method for detecting vaccine-derived polioviruses in clinical samples.

Authors:  Natalia I Romanenkova; Sophie Guillot; Nadejda R Rozaeva; Radu Crainic; Maina A Bichurina; Francis Delpeyroux
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

9.  Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR.

Authors:  David R Kilpatrick; Karen Ching; Jane Iber; Qi Chen; Su-Ju Yang; Lina De; A J Williams; Mark Mandelbaum; Hong Sun; M Steven Oberste; Olen M Kew
Journal:  J Virol Methods       Date:  2013-12-07       Impact factor: 2.014

10.  High frequency and diversity of species C enteroviruses in Cameroon and neighboring countries.

Authors:  Serge Alain Sadeuh-Mba; Maël Bessaud; Denis Massenet; Marie-Line Joffret; Marie-Claire Endegue; Richard Njouom; Jean-Marc Reynes; Dominique Rousset; Francis Delpeyroux
Journal:  J Clin Microbiol       Date:  2012-12-19       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.